What patients, if any, would you offer adjuvant TKI instead of durvalumab after chemoRT in non-EGFR mutated Stage III NSCLC?   

Given LAURA has changed the approach for EGFR mutated, would you utilize the same approach for any of the other mutation types such as ALK, ROS1, MET, or RET?